-
1 Comment
Nyrada Inc is currently in a long term uptrend where the price is trading 18.3% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Nyrada Inc gets an overall score of 2/5.
Exchange | AU |
---|---|
CurrencyCode | AUD |
ISIN | AU0000070195 |
Industry | Biotechnology |
Sector | Healthcare |
Beta | 0.63 |
---|---|
Market Cap | 22M |
PE Ratio | None |
Target Price | None |
Dividend Yield | None |
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its develops oral Proprotein Convertase Subtilisin/Kexin Type 9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; and neuroprotectant drug to reduce long-term disability in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NYR.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025